{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:51:05Z","timestamp":1769849465152,"version":"3.49.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (\u22643 copies). MM patients carrying gain of 1q21 (\u22653 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM.<\/jats:p>","DOI":"10.3389\/fonc.2021.757664","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T12:54:41Z","timestamp":1635166481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Cyrus","family":"Khandanpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subbaiah Chary","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asta","family":"F\u00f6rsti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00824","article-title":"Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications","volume":"9","author":"Moroy","year":"2019","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s42003-019-0329-2","article-title":"Genome-Wide Interaction and Pathway-Based Identification of Key Regulators in Multiple Myeloma","volume":"2","author":"Chattopadhyay","year":"2019","journal-title":"Commun Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.exphem.2016.05.004","article-title":"Epigenetic Therapy as a Novel Approach for GFI136N-Associated Murine\/Human AML","volume":"44","author":"Botezatu","year":"2016","journal-title":"Exp Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.997.997","article-title":"A Human Variant of Growth Factor Independence 1 (GFI136N) Predisposes to Myeloid Leukemia In Mice","volume":"116","author":"Khandanpour","year":"2010","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/ng.993","article-title":"Common Variation at 3p22.1 and 7p15.3 Influences Multiple Myeloma Risk","volume":"44","author":"Broderick","year":"2011","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2733","article-title":"Common Variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 Influences Multiple Myeloma Risk","volume":"45","author":"Chubb","year":"2013","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41375-019-0703-6","article-title":"Genetic Predisposition for Multiple Myeloma","volume":"34","author":"Pertesi","year":"2020","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of Multiple Risk Loci and Regulatory Mechanisms Influencing Susceptibility to Multiple Myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple Myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 Expressed in Bone Marrow Stromal Cells Is a Novel Osteoblast Suppressor in Patients With Multiple Myeloma Bone Disease","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.07.011","article-title":"A Recurrent Network Involving the Transcription Factors PU.1 and Gfi1 Orchestrates Innate and Adaptive Immune Cell Fates","volume":"31","author":"Spooner","year":"2009","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247","article-title":"IMWG Consensus on Risk Stratification in Multiple Myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of Outcome in Newly Diagnosed Myeloma: A Meta-Analysis of the Molecular Profiles of 1905 Trial Patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.80","article-title":"Phase III Trial of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Bortezomib, Doxorubicin and Dexamethasone (PAd) in Newly Diagnosed Myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-019-0750-5","article-title":"Prospective Target Assessment and Multimodal Prediction of Survival for Personalized and Risk-Adapted Treatment Strategies in Multiple Myeloma in the GMMG-MM5 Multicenter Trial","volume":"12","author":"Hose","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1093\/nar\/gks461","article-title":"Camera: A Competitive Gene Set Test Accounting for Inter-Gene Correlation","volume":"40","author":"Wu","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent Gain of Chromosome Band 1q21 in Plasma-Cell Dyscrasias Detected by Fluorescence In Situ Hybridization: Incidence Increases From MGUS to Relapsed Myeloma and is Related to Prognosis and Disease Progression Following Tandem Stem-Cell Transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0166-1","article-title":"Reduced Expression But Not Deficiency of GFI1 Causes a Fatal Myeloproliferative Disease in Mice","volume":"33","author":"Fraszczak","year":"2019","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.exphem.2016.04.001","article-title":"GFI1(36N) as a Therapeutic and Prognostic Marker for Myelodysplastic Syndrome","volume":"44","author":"Botezatu","year":"2016","journal-title":"Exp Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T12:54:43Z","timestamp":1635166483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":21,"alternative-id":["10.3389\/fonc.2021.757664"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.757664","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"article-number":"757664"}}